Kaituo Pharmaceutical Hong Kong Stock Exchange announced that its self-developed phase II clinical trial of GT20029 tincture, a novel proteolytic chimeric (PROTAC) compound targeting androgen receptors (AR), was used topically to treat male androgenic alopecia (alopecia or AGA). The results were statistically significant and clinically significant, and the safety and tolerability were good. Based on the results of this phase II clinical trial, the company will actively deploy subsequent clinical strategies for GT20029, such as carrying out phase III clinical trials for male hair loss in China and phase II clinical trials in the US. In addition, the company is also preparing to conduct a phase II clinical trial of GT20029 for acne treatment.
开拓药业：GT20029治疗男性脱发中国II期临床试验达到主要终点
Pioneering the pharmaceutical industry: GT20029 Chinese phase II clinical trial to treat male hair loss reached the main end
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.